GLEOSTINE lomustine
Drug Class
Alkylating agent烷化剂
Mechanism
Alkylates DNA and RNA, cross-linking nucleic acid strands and inhibiting macromolecular synthesis in cancer cells.使 DNA 和 RNA 烷基化，导致核酸链交联并抑制癌细胞中的大分子合成。
Approved Indication
Treatment of patients with brain tumors (primary and metastatic) and Hodgkin's lymphoma (as second-line therapy), in addition to other modalities or in combination regimens.作为联合治疗或单药方案，用于治疗脑肿瘤（原发性和转移性）以及霍奇金淋巴瘤（作为二线治疗）。
What This Means For Patients
Gleostine (lomustine) is an oral nitrosourea chemotherapy agent that has been a standard treatment for brain cancer and refractory Hodgkin's lymphoma since the 1970s. It crosses the blood-brain barrier effectively. It is available under the special-import policy in the Hainan Boao Lecheng pilot zone.洛莫司汀（Gleostine）是一种口服亚硝基脲类化疗药物，自20世纪70年代以来一直是脑部肿瘤和难治性霍奇金淋巴瘤的标准治疗方案。它能有效穿过血脑屏障。该药物已通过先行区特许进口政策引入博鳌乐城。
Regulatory Approvals
Not yet documented.
Pivotal Clinical Evidence
No peer-reviewed pivotal trial on file yet.
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.